NCT00313729 · OUTCOME

Time to Tumor Progression

Temozolomide in Treating Patients With Low-Grade Glioma · Source last updated 2019-02-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEDIAN
Unit: years
Interval / dispersion: 95% Confidence Interval
Time frame: time from registration until date of the first documented progression, an average of 1 year

What was measured

Progressive disease was defined as definite enlargement of any existing lesion or any new lesion based on modified Macdonald's criteria.

Temozolomide temozolomide: Chemotherapy

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Temozolomide	120

Source class 1

Values in years · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Temozolomide	3.8	Not reported	3.0	5.0	Not reported

Complete source fields

classes

denoms

description

Progressive disease was defined as definite enlargement of any existing lesion or any new lesion based on modified Macdonald's criteria.

dispersion Type

95% Confidence Interval

groups

param Type

MEDIAN

reporting Status

POSTED

time Frame

time from registration until date of the first documented progression, an average of 1 year

title

Time to Tumor Progression

type

SECONDARY

unit Of Measure

years

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice